late
decemb
outbreak
emerg
diseas
due
novel
coronaviru
name
latter
start
wuhan
china
rapidli
spread
china
outsid
declar
epidem
pandem
march
th
accord
recent
chines
stud
patient
present
mild
diseas
overal
casefat
rate
reach
patient
age
year
age
year
howev
probabl
import
number
asymptomat
carrier
popul
thu
mortal
rate
probabl
overestim
franc
face
wave
case
march
th
thu
urgent
need
effect
treatment
treat
symptomat
patient
also
decreas
durat
viru
carriag
order
limit
transmiss
commun
among
candid
drug
treat
reposit
old
drug
use
antivir
treatment
interest
strategi
knowledg
safeti
profil
side
effect
posolog
drug
interact
well
known
recent
paper
report
inhibitor
effect
remdesivir
new
antivir
drug
chloroquin
old
antimalari
drug
growth
vitro
earli
clinic
trial
conduct
chines
patient
show
chloroquin
signific
effect
term
clinic
outcom
viral
clearanc
compar
control
group
chines
expert
recommend
patient
diagnos
mild
moder
sever
case
pneumonia
without
contraind
chloroquin
treat
mg
chloroquin
twice
day
ten
day
hydroxychloroquin
analogu
chloroquin
demonstr
antisarscov
activ
vitro
hydroxychloroquin
clinic
safeti
profil
better
chloroquin
longterm
use
allow
higher
daili
dose
fewer
concern
drugdrug
interact
team
comprehens
experi
success
treat
patient
chronic
diseas
due
intracellular
bacteria
q
fever
due
coxiella
burnetii
whippl
diseas
due
tropheryma
whipplei
longterm
hydroxychloroquin
treatment
mgday
month
sinc
year
therefor
start
conduct
clinic
trial
aim
assess
effect
hydroxychloroquin
patient
approv
french
ministri
health
report
describ
earli
result
focus
virolog
data
patient
receiv
hydroxychloroquin
compar
control
group
ongo
studi
coordin
infect
univers
hospit
institut
marseil
patient
propos
treatment
hydroxychloroquin
recruit
manag
marseil
centr
control
without
hydroxychloroquin
treatment
recruit
marseil
nice
avignon
center
locat
south
franc
hospit
patient
confirm
includ
studi
fulfil
two
primari
criteria
age
year
ii
pcr
document
carriag
nasopharyng
sampl
admiss
whatev
clinic
statu
patient
exclud
known
allergi
hydroxychloroquin
chloroquin
anoth
known
contraind
treatment
studi
drug
includ
retinopathi
defici
qt
prolong
breastfeed
pregnant
patient
exclud
base
declar
pregnanc
test
result
requir
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
includ
studi
patient
meet
inclus
criteria
give
consent
particip
studi
written
inform
sign
consent
obtain
adult
particip
year
parent
legal
guardian
minor
year
inform
document
clearli
indic
risk
benefit
associ
particip
studi
given
patient
patient
receiv
inform
clinic
statu
care
regardless
whether
particip
studi
regard
patient
identif
studi
number
assign
sequenti
includ
particip
accord
rang
patient
number
alloc
studi
centr
studi
patient
seen
baselin
enrol
initi
data
collect
treatment
daili
followup
day
day
patient
receiv
standard
clinic
examin
possibl
nasopharyng
sampl
collect
clinic
data
collect
use
standard
questionnair
patient
marseil
center
propos
oral
hydroxychloroquin
sulfat
mg
three
time
per
day
ten
day
preliminari
phase
enrol
children
treatment
group
base
data
indic
children
develop
mild
symptom
patient
refus
treatment
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
exclus
criteria
serv
control
marseil
centr
patient
center
receiv
hydroxychloroquin
serv
control
symptomat
treatment
antibiot
measur
prevent
bacteri
superinfect
provid
investig
base
clinic
judgment
hydroxychloroquin
provid
nation
pharmaci
franc
nomin
demand
patient
group
three
categori
asymptomat
upper
respiratori
tract
infect
urti
present
rhiniti
pharyng
isol
lowgrad
fever
myalgia
lower
respiratori
tract
infect
lrti
present
symptom
pneumonia
bronchiti
nativ
hydroxychloroquin
dose
patient
serum
sampl
uhplcuv
use
previous
describ
protocol
peak
chromatogram
min
retent
correspond
hydroxychloroquin
metabolit
serum
concentr
metabolit
deduc
uv
absorpt
hydroxychloroquin
concentr
consid
concentr
provid
estim
initi
serum
hydroxychloroquin
concentr
cultur
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
patient
liquid
collect
nasopharyng
swab
pass
pore
size
centrifug
filter
merck
millipor
darmstadt
germani
inocul
well
cultur
micropl
well
contain
vero
cell
atcc
minimum
essenti
medium
cultur
medium
fetal
calf
serum
glutamin
centrifig
g
micropl
incub
plate
observ
daili
evid
cytopathogen
effect
presumpt
detect
viru
supernat
done
use
sem
hitachi
confirm
specif
rtpcr
primari
endpoint
virolog
clearanc
postinclus
secondari
outcom
virolog
clearanc
overtim
studi
period
clinic
followup
bodi
temperatur
respiratori
rate
long
stay
hospit
mortal
occurr
sideeffect
assum
efficaci
hydroxychloroquin
reduc
viral
load
day
power
type
error
rate
loss
followup
calcul
total
patient
ie
case
hydroxychloroquin
group
control
group
would
requir
analysi
fleiss
cc
statist
differ
evalu
pearson
chisquar
fisher
exact
test
categor
variabl
appropri
mean
quantit
data
compar
use
student
ttest
analys
perform
openepi
version
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
sideeffect
describ
paper
end
trial
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
mean
hydroxychloroquin
serum
concentr
proport
patient
neg
pcr
result
nasopharyng
sampl
significantli
differ
treat
patient
control
day
postinclus
tabl
postinclus
hydroxychloroquinetr
patient
virologicali
cure
compar
control
group
p
compar
effect
hydroxychloroquin
treatment
singl
drug
effect
could
isol
clinic
sampl
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
ethic
reason
first
result
signific
evid
decid
share
find
medic
commun
given
urgent
need
effect
drug
current
pandem
context
show
hydroxychloroquin
effici
clear
viral
nasopharyng
carriag
patient
three
six
day
patient
signific
differ
observ
hydroxychloroquinetr
patient
control
start
even
postinclus
result
great
import
recent
paper
shown
mean
durat
viral
shed
patient
suffer
covid
recent
chines
team
publish
result
studi
demonstr
chloroquin
hydroxychloroquin
inhibit
vitro
hydroxychloroquin
found
potent
chloroquin
vitro
result
corrobor
clinic
result
target
valu
indic
paper
reach
experi
safer
dosedepend
toxic
profil
hydroxychloroquin
human
compar
chloroquin
allow
use
clinic
dose
hydroxychloroquin
observ
vitro
preliminari
result
also
suggest
synergist
effect
combin
hydroxychloroquin
azithromycin
azithromycin
shown
activ
vitro
zika
ebola
virus
prevent
sever
respiratori
tract
infect
administr
patient
suffer
viral
infect
find
explor
know
whether
combin
effect
especi
sever
case
specul
potenti
risk
sever
qt
prolong
induc
associ
two
drug
establish
yet
consid
treatment
cost
benefit
risk
evalu
individu
studi
combin
need
sinc
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
combin
may
act
antivir
therapi
prevent
bacteri
superinfect
caus
failur
hydroxychloroquin
treatment
investig
test
isol
strain
nonrespond
analyz
genom
analyz
host
factor
may
associ
metabol
hydroxychloroquin
exist
hydroxychloroquin
failur
two
patient
mother
son
suggest
last
mechan
resist
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
control
patient
center
marseil
underw
daili
sampl
sampl
everi
day
consid
posit
pcr
actual
posit
day
day
day
miss
data
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
